Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study

Philip L. Molyneaux M.D.[1,2], Nikhil A. Hirani M.D.[3,4], Collin C.K. Chia M.D.[5], Tejaswini Kulkarni M.D.[6], Tanzira Zaman M.D.[7], Robert J. Kaner M.D.[8], Cory M. Hogaboam Ph.D.[9,10], BreAnne MacKenzie Ph.D.[10], Ana Lucia Coelho Ph.D.[9],Yago Amigo Pinho Jannini-Sa Ph.D.[9], Brian Windsor Ph.D.[10], Sydney Kruger[10], Dale J. Christensen Ph.D.[11], Steven A. Shoemaker M.D.[10], Andreas Günther M.D., Ph.D.[12,13,14,15]

[1]Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

[2]National Heart and Lung Institute, Imperial College London, London, United Kingdom

[3]Edinburgh Lung Fibrosis Clinic, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

[4]Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, United Kingdom

[5]Launceston Respiratory and Sleep Center, Launceston General Hospital, Launceston, TAS, Australia

[6]Pulmonary, Allergy & Critical Care Medicine, University of Alabama Birmingham, Alabama, United States

[7]Pulmonary & Critical Care Medicine, Cedars Sinai Medical Center, Los Angeles, California, United States

[8]Weill Cornell Medicine, 1300 York Avenue, New York, New York, United States

[9]Women's Guild Lung Institute, Cedars Sinai Medical Center, Los Angeles, California, United States

[10]Rein Therapeutics, Inc., Austin, Texas, United States

[11]Department of Medicine, Duke University Medical School, Durham, North Carolina, United States [12]Center for Interstitial and Rare Lung Diseases, Justus-Liebig-University, University of Giessen and Marburg Lung Center, Member of the German Center for Lung Research, Giessen, Germany

[13]Lung Clinic, Evangelisches Krankenhaus Mittelhessen, Giessen, Germany

[14]Institute for Lung Health (ILH), Giessen, Germany

[15]Excellence Cluster Cardiopulmonary Institute (CPI), Giessen, Germany

Corresponding Author: Professor Andreas Günther, M.D. Center for Interstitial and Rare Lung Diseases, Justus-Liebig-University, Giessen University Hospital Giessen / Marburg, Klinikstrasse 36, 35392 Giessen, Germany. andreas.guenther@innere.med.uni-giessen.de

Author Contributions: All authors contributed substantially to this study. Study Concept and design: P.L.M., N.A.H., C.K.C., T.K., T.Z., R.J.K., S.A.S., S.K., A.G. Acquisition, analysis, interpretation of the data: C.M.H., B.M., D.J.C., S.A.S., S.K. A.L.C., YA.P.J., B.W. Review and approval of the manuscript: P.L.M., N.A.H., C.K.C., T.K., T.Z., R.K., S.A.S., S.K., C.M.H., B.M., B.W., A.G.

ORCID IDs: Philip L. Molyneaux 0000-0003-1301-8800; Nikhil A. Hirani 0000-0001-8854-3605; Tejaswini Kulkarni 0000-0002-4251-4988; Tanzira Zaman M.D. 0000-0003-0286-4382; Robert J. Kaner M.D. 0000-0003-0527-576X; Cory M. Hogaboam 0000-0003-3366-4850; BreAnne MacKenzie 0000-0002-8336-6408; Ana Lucia Coelho 0000-0001-5087-6842; Yago Amigo Pinho Jannini-Sa 0000-0003-4137-1257

Supported by Rein Therapeutics, Inc. LINESBIR: R43HL167437

Running Title**:** Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis

Artificial Intelligence Disclaimer: No artificial intelligence tools were used in the writing of this manuscript.

At A Glance

Scientific Knowledge on the Subject: Current standard of care therapies for IPF do not halt or reverse disease progression, and systemic side effects commonly result in discontinued use. LTI-03 is a caveolin scaffolding domain (CSD) peptide formulated as an excipient-free dry powder for the treatment of IPF. It has demonstrated anti-fibrotic and epithelial protective effects in animal models of fibrosis and in IPF precision cut lung slices via putative replenishment of endogenous Cav-1 signaling, which is lost in fibrotic diseases.

What This Study Adds to the Field: The results of this study support the conclusion that LTI-03 was well tolerated in patients with IPF at doses of 5 and 10 mg/day. Exploratory biomarker analyses from deep bronchial brushings suggested that positive pharmacodynamic effects were achieved on target cell types. Taken together, these results support the initiation of a Phase 2 efficacy study in patients with IPF.

ABSTRACT

Rationale: LTI-03 is a novel inhaled therapeutic in development for idiopathic pulmonary fibrosis

(IPF). LTI-03 has been shown to promote alveolar epithelial cell survival and reduce profibrotic

protein expression in experimental models of lung disease.

Objectives: To evaluate the safety and pharmacokinetics (PK) of LTI-03 and effects on disease

biomarkers in patients with IPF.

Methods: This Phase 1b, randomized, controlled, dose-escalation study randomized 24

participants, 3:1 into 2 sequential dose cohorts, to receive inhaled LTI-03 (5 or 10 mg/day) or

placebo for 14 days. The primary endpoint was the incidence of treatment-related adverse events

(TEAEs). Exploratory analyses included PK and change from baseline in fibrosis-related and

epithelial integrity-related biomarkers in plasma, peripheral blood mononuclear cells (PBMCs),

and deep bronchial brushings (DBB).

Measurements and Main Results: Inhaled LTI-03 was well-tolerated, with no treatment-related

AEs leading to treatment discontinuation. All TEAEs were mild or moderate in severity. Cough

was the most common TEAE and the only treatment-related TEAE experienced by more than 1

participant. There was no evidence of airway obstruction by symptoms or spirometry. LTI-03 did

not induce inflammation (phosphorylated AKT) in PBMCs. In DBB samples, LTI-03 significantly

reduced the expression of interleukin-11, chemokine ligand 7, thymic stromal lymphopoietin, and

galectin 7; dose-related reductions were also observed for collagen type 1 alpha chain 1 and plasma

surfactant protein D.

Conclusions: Inhaled LTI-03 exhibited a favorable safety and tolerability profile over 14 days.

Exploratory biomarker analyses suggest a positive effect on epithelial homeostasis and

corresponding antifibrotic effects.

Abstract Word Count: 245 words

Clinical study registered with www.clinicaltrials.gov (NCT05954988)

Keywords: IPF; fibrosis; alveolar epithelial cells; inhalation drug administration; deep bronchial

brushings

Data sharing statement: Rein Therapeutics, Inc. ("Rein") understands and acknowledges the

need to share clinical study data with the research community in an open and transparent manner

and has provided de-identified patient data in the manuscript. Rein will not consider further

requests pertaining to clinical data outside of what has been accepted and published by the journal.

Any queries regarding clinical study data must be submitted in writing to info@reintx.com.

A data supplement for this article is available via the Supplements tab at the top of the online
article.

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal, age-associated lung disease with poor survival (1). The pathogenesis of IPF is characterized by apoptosis and senescence of alveolar epithelial type 2 cells, proliferation and accumulation of activated myofibroblasts, deposition of extracellular matrix (ECM), and fibrosis, resulting in progressive dyspnea and loss of lung function, especially forced vital capacity (FVC) (2, 3). The two approved anti-fibrotic drugs, nintedanib and pirfenidone, slow FVC decline (2). Also, both drugs may be poorly tolerated due to gastrointestinal or cutaneous side effects, leading to frequent discontinuation (4, 5). Hence, there is an urgent need for therapies better targeting the underlying causes of IPF and other interstitial lung diseases; in particular, alveolar protective treatments that may act to restore healthy lung function with a more favorable tolerability profile.

LTI-03 is a synthetic oligopeptide consisting of seven natural L-amino acids of the Caveolin-1 scaffolding domain (CSD) of the Caveolin-1 protein (Cav-1), a structural protein that plays a critical role in regulating lung repair and cellular movement by restoring pathways that both promote epithelial health and halt fibrosis in the lung (6-8). Cav-1 expression in pulmonary fibroblasts and alveolar epithelial cells is decreased in transgenic and rodent bleomycin models of lung injury and in the lungs of patients with IPF (9-11). Augmentation of endogenous Cav-1 levels and supplementation of exogenous CSD peptide have been shown to suppress lung fibrosis (6, 9, 10, 12, 13). Most notably, antifibrotic and epithelial supportive effects of LTI-03 have been demonstrated in experimental animal models of lung fibrosis (14-16), in human IPF precision cut lung slices (17), and in human IPF alveolar organoids (18).

While LTI-03 first demonstrated efficacy upon intraperitoneal administration in mouse models of IPF (19), limited aqueous solubility necessitated an alternate formulation and delivery strategy.

Micronized LTI-03 is made without the addition of excipients, has excellent stability, and

importantly, has particle properties suitable for deep lung deposition (20). LTI-03 (2.5 mg/capsule)

is self-administered by study participants using a commercially available dry-powder inhaler.

This study reports the safety and tolerability of LTI-03 following twice daily inhaled

administration of LTI-03 (total doses of 5 mg/day or 10 mg/day) to participants with IPF for 14

days. Finally, LTI-03 treatment-related, beneficial impacts on exploratory biomarkers, which were

selected based on nonclinical and translational experiments, are presented and discussed.

METHODS

Study Population

Eligible participants were ≥ 40 years of age with a diagnosis of IPF per ATS/ERS/JRS/ALAT guidelines (21), made within 3 years of enrollment, with FVC percent predicted ≥ 40%, DLCO percent predicted between 30% and 80%, and $FEV_1/FVC \geq 0.7$. For additional inclusion and exclusion criteria, see the online supplement.

Study Design

This was a Phase 1b, randomized, double-blind, placebo-controlled, dose escalation study conducted at 6 sites in the United States, United Kingdom, Germany, and Australia (ClinicalTrials.gov: NCT05954988). The primary objective was to assess the safety and tolerability of inhaled LTI-03 compared to placebo in patients with IPF. Exploratory objectives were to assess LTI-03 pharmacokinetics (PK) and pharmacodynamics.

The study had 3 periods: screening (up to 21 days), treatment (14 days) and follow-up (7 days), with study visits on Days 1, 7, 14, and 21 (**Figure 1**).

Eligible participants were randomized 3:1 to LTI-03 or placebo into 2 sequential cohorts (n=12 per cohort). The 5 mg/day (low-dose) cohort received 2.5 mg LTI-03 or placebo twice daily (BID) and the 10 mg/day (high dose) cohort received 5 mg BID LTI-03 or placebo. Randomization was performed by interactive response system. Study staff were blinded to treatment assignment throughout the study.

The study complied with Good Clinical Practice and the Declaration of Helsinki. All participants provided written informed consent. The study protocol and informed consent were approved by each site's Institutional Review Board or Independent Ethics Committee.

Study Assessments

Safety and tolerability assessments were performed through treatment and follow-up and included

evaluation of treatment-emergent adverse events (TEAEs), concomitant medications, physical

examinations, vital signs, 12-lead electrocardiograms, clinical laboratory assessments, spirometry,

and cough symptoms using the Leicester Cough Questionnaire (LCQ) cough visual analog scale

(VAS) (22). Bronchoscopies performed at screening and Day 14 collected fluid specimens by

bronchoalveolar lavage (BAL) and/or broncho-absorption (BA), and deep bronchial brushings

(DBBs). Blood was collected for PK, peripheral blood mononuclear cells (PBMCs), and biomarker

assessments throughout the study. Study staff monitored participants' self-administration of study

drug (the morning dose) during on-site visits and symptoms were monitored for at least 1 hour.

Statistical Analyses

The primary endpoint was the incidence of TEAEs reported from Day 1 through follow-up. TEAEs

were coded using MedDRA (Version 26.1) and graded using the National Cancer Institute

Common Terminology for Adverse Events (CTCAE) Version 5. Safety analyses included all

participants who received study drug. A sample size of 18 LTI-03 participants provided a 60%

chance of detecting an AE with a true incidence rate of 5% and an 85% chance of detecting a more

common AE with a true incidence rate of 10%. Placebo participants in each cohort were pooled

for safety and biomarker analyses.

No secondary endpoints were specified. For the exploratory biomarker analysis, to test the

hypothesis that LTI-03 would reduce the levels of the selected biomarkers, change from baseline

to Day 14 was analyzed using a one-tailed, un-paired, parametric t-test, comparing pooled placebo

samples to each LTI-03 dose group and LTI-03 combined.

See the online supplement for additional assessment and analysis information.

Results

Participant Disposition and Characteristics

Twenty-four participants with IPF met eligibility criteria and were randomized between June 2023 and October 2024 into the 2 sequential dose cohorts (**Figure 2**). No participant discontinued study treatment due to a TEAE, and all completed the study. LTI-03 dosing was incorrectly stopped by the Investigator on Day 14 for 1 participant in the LTI-03 5 mg/day group due to "met stopping criteria with decrease in FEV1"; however, the protocol stopping criteria also required an associated decrease from baseline in the FEV1/FVC ratio, which was not met and would have supported continued dose administration. At baseline, demographics and disease characteristics were generally well balanced across the treatment groups (**Table 1**). No prior use of any approved or investigational antifibrotic drug was reported for any participant.

Safety and Tolerability

LTI-03 was well tolerated over 14 days of twice daily dosing at total doses of 5 and 10 mg/day. The incidence of TEAEs was 66.7%, 77.8%, and 50% for the LTI-03 5 mg/day, LTI-03 10 mg/day, and placebo groups, respectively **(Table 2).** There were no fatalities or TEAEs leading to treatment discontinuation. One (4.2%) participant in the LTI-03 10 mg/day group experienced an unrelated SAE of Grade 2 post-bronchoscopy fever requiring overnight inpatient observation. Most TEAEs in all dose groups were Grade 1 in severity. The total number of participants reporting Grade 2 TEAEs was low (n=3; 16.7%), and there were no TEAEs in any group that were Grade 3 or higher. Cough was the most common TEAE, reported by 3 (33.3%), 5 (55.6%), and 2 (33.3%) participants in the LTI-03 5 mg/day, LTI-03 10 mg/day, and placebo groups, respectively. Rhinorrhea, reported by 1 participant in each of the LTI-03 treatment groups, was the only other TEAE reported by more than 1 participant in any group.

Grade 2 cough related to study drug that resolved on the same day was reported in 1 (11.1%)

participant each in the LTI-03 5 mg/day and LTI-03 10 mg/day groups, respectively. Cough was

the only study drug-related TEAE experienced by more than 1 participant. None of the study drug-

related TEAEs was an SAE or led to treatment discontinuation.

No apparent treatment- or dose-related trends in clinical laboratory parameters, vital sign

measurements, ECG results, or physical examination findings were observed during the study.

Mean changes from baseline in spirometry were not clinically significant.

Participants reported cough symptoms at baseline as measured by LCQ and VAS scores (**Table 1**).

No clinically significant changes in the LCQ total score or the cough VAS were observed during

the treatment period for any treatment group.

Pharmacokinetics

All post-dose plasma concentrations of LTI-03 were below the limit of quantification (BLQ) on

Days 1, 7, and 14. LTI-03 concentrations in bronchoalveolar lavage fluid (BALF) at Day 14 were

quantifiable in 3 participants in the LTI-03 5 mg/day group (1.55, 6.60, and 1.37 ng/mL) and 2

participants in the LTI-03 10 mg/day group (2.57 and 14.7 ng/mL); all other BALF sample

concentrations were BLQ.

Exploratory Biomarkers

The exploratory biomarker strategy was informed by: 1) Caveolin-1 biology in the context of

fibrosis (6, 23-26); 2) IPF pathogenesis (27, 28); and importantly 3) LTI-03 pharmacodynamic

data from a variety of translational models (16-18). Based on these data, it was hypothesized that

LTI-03 would reduce these biomarkers in a clinical setting. In pooled DBB samples, LTI-03

significantly reduced expression of multiple profibrotic proteins including interleukin 11 (IL-11),

chemokine (C-X-C motif) ligand 7 (CXCL7), thymic stromal lymphopoietin (TSLP), and galectin

7 (GAL-7) **(Table 3; Supplemental Figure E1)**. Dose-dependent trends (reductions), mostly

reaching significance, were observed in 5 biomarkers, including collagen type 1 alpha chain 1

(COL1A1), CXCL7, TSLP, and GAL-7. Plasma levels of surfactant protein D (SP-D), an indicator

of epithelial cell stress, was decreased by 5% in the LTI-03 10 mg/day group at 14 days of

treatment although differences did not reach statistical significance. LTI-03 did not induce

inflammation in PBMCs in either cohort, as measured by phosphorylated (p) AKT.

Discussion

LTI-03 is a caveolin scaffolding domain (CSD) peptide formulated as an excipient free dry powder

for inhalation. This first-in-patient study evaluated the safety and tolerability of LTI-03 compared

to placebo when administered twice daily for 14 days in 24 participants with IPF. Participants were

diagnosed within 3 years of screening per guidelines; none reported receiving prior treatment with

nintedanib or pirfenidone. Inhaled LTI-03 at doses of 5 mg/day (2.5 mg BID) and 10 mg/day (5

mg BID) was well tolerated and all 24 participants completed the study. There were no TEAEs

that led to treatment discontinuation. The majority of TEAEs were mild (Grade 1) in severity; only

3 (16.7%) participants reported Grade 2 AEs, and none (0%) reported TEAEs Grade 3 or higher.

One participant in the LTI-03 5 mg/day group experienced an SAE of Grade 2 fever following

bronchoscopy that warranted overnight admission for observation; they had no clinical signs or

symptoms of infection, no antibiotic treatment was required during or after hospital discharge, and

the event was considered unrelated to study drug. Post-procedural fever is a known complication

following bronchoscopy (29).

Cough was the most frequently reported TEAE for 44% of participants who received LTI-03,

compared to 33% who received placebo, and the only study drug-related TEAE experienced by

more than 1 participant. The majority of cough TEAEs were mild in severity except for 2 study

drug-related TEAEs of Grade 2 severity, each resolving on the same day: one occurred as a single

episode and the other occurred intermittently. All other study drug-related TEAEs of cough were

intermittent in frequency and Grade 1 in severity, occurring intermittently after study drug

administration. Other than rhinorrhea, which was reported for 1 participant each in the LTI-03

5 mg/day and 10 mg/day groups, no other TEAEs were reported by more than 1 participant.

Participants self-reported the effect of LTI-03 on their chronic cough symptoms and daily life

using the LCQ, and the severity of their cough symptoms using a visual analogue scale that rated

cough severity (0 = no cough to 100 = worst cough ever). Importantly, inhalation of the study drug

did not appear to negatively affect participants' quality of life or worsen pre-existing chronic cough

symptoms.

Spirometry was performed pre- and post-dose (30 and 60 minutes) as a safety assessment to

quantify any acute effects of study drug inhalation on airways. There were no clinically significant

differences between the LTI-03 and placebo groups in mean changes in FEV_1 and FVC

immediately following study drug dosing and over the course of the treatment period. There was

no evidence by either spirometry or participant-reported symptoms of airway obstruction

following study drug inhalation.

Systemic levels of LTI-03 measured immediately after LTI-03 inhalation were undetectable in all

participants regardless of LTI-03 dose, similar to healthy volunteers at the same doses (data on

file). Canine toxicology studies have shown that this is likely due to absorption of LTI-03, a

hydrophobic peptide, by lung tissue (unpublished data). Conversely, LTI-03 was detectable in

BALF samples collected after inhalation for 5 participants (3 in the 5 mg/day; 2 in the 10 mg/day),

confirming distribution of LTI-03 into the lung. The measurement of LTI-03 in BALF was limited

by the low solubility of hydrophobic LTI-03 in aqueous solutions; differences in time between

drug inhalation and sample collection via bronchoscopy; and variability in the volume of BALF

sample collected.

It is hypothesized that IPF pathophysiology is driven by the persistent microinjury of alveolar

epithelial cells leading to apoptosis and necrosis, downstream aberrant fibroblast activation, and

abnormal accumulation of extracellular matrix (3). Preclinical data in animal models of fibrosis

and in precision cut lung slices sourced from end-stage IPF patients have demonstrated that LTI-

03 has a novel mechanism of action in that it attenuates profibrotic pathways and supports

maintenance of alveolar epithelial cell homeostasis (16, 17, 19).

Exploratory biomarker analyses demonstrated that 14 days of LTI-03 administration resulted in

downregulation of key biomarkers of fibrosis and epithelial cell distress in the lung, the primary

site of LTI-03 activity. Statistically significant reductions ($p \leq 0.05$) in the expression of multiple

profibrotic proteins active in both pathologic basal-like cells and fibroblasts was observed after 14

days of LTI-03 treatment for IL-11, CXCL7, TSLP and GAL-7 with dose-dependent trends.

TSLP is a pro-inflammatory cytokine that is released following epithelium damage and drives

pathological processes such as mucus hypersecretion and airway remodeling (30). TSLP levels are

significantly elevated in BALF (31) and lung tissue from patients with IPF (32) and

immunohistochemical studies have localized elevated TSLP expression to alveolar epithelial cells

and fibrotic foci (32). In IPF, TSLP may promote fibrogenesis by activating fibroblasts and

recruiting immune cells to sites of epithelial injury (32). Statistically significant reductions in

TSLP following LTI-03 treatment support the hypothesis that LTI-03 may have positive effects

on lung epithelial cell health.

Immunohistochemical analyses of IPF lung tissue have shown intense GAL-7 expression localized

to the alveolar and bronchiolar epithelium and alveolar septum (11). The reductions in GAL-7 in

DBB samples suggest that inhaled LTI-03 had a targeted effect deep in the lung.

Plasma levels of SP-D, an indicator of epithelial cell health, were decreased by 5% (p=0.102) in

the high dose LTI-03 (10 mg/day) group after 14 days of treatment, although this did not reach

statistical significance. Increased circulating SP-D levels are significantly linked to decline in lung

function and are responsive to standard of care (33, 34). Decreases in SP-D levels with LTI-03

compared to placebo after the short duration of 14 days of dosing are comparable to those described

in other trials after longer treatment durations, notably the CAPACITY study of pirfenidone (5%

at 12 weeks) (35) and the INMARK study of nintedanib (4% at 12 weeks) (36, 37). Another

positive finding was that LTI-03 did not induce inflammation in PBMCs in either LTI-03 group,

measured by pAKT, a safety marker for inflammation in this analysis.

There remains an unmet medical need for safe and effective treatments that target epithelial cell

injury in IPF. Inhaled therapies can facilitate increased drug delivery to the site of disease while

minimizing systemic off-target effects. The overall low incidence of serious, treatment-related, or

severe TEAEs, absence of treatment discontinuations due to a TEAE, and no detectable systemic

absorption suggest that inhaled LTI-03 has the potential for a more favorable safety, tolerability,

and adherence profile compared to the currently approved, systemically administered treatments.

Preclinical data in experimental models and evidence of active LTI-03 pharmacodynamics in this

study suggest that LTI-03 may regulate processes driving both lung repair and fibrosis.

Limitations in the interpretation of this study include the small sample size (n=24) and a short

treatment duration of 14 days. A sample size of 24 participants was planned to ensure that safety

and tolerability of LTI-03 were adequately assessed while minimizing unnecessary participant

exposure. No conclusion of LTI-03 effects on disease progression can be derived from the data

collected. Larger studies of longer treatment durations in patients with IPF will be required to

confirm and expand upon the findings of this first-in-patient study.

This study showed that the administration of inhaled LTI-03 to participants with IPF was safe and

well-tolerated at doses of 5 and 10 mg/day. Additionally, an exploratory analysis of pro-fibrotic,

epithelial health, and inflammatory biomarkers suggests a potential pharmacodynamic benefit of

LTI-03 administration without the induction of inflammation. These encouraging data support

further evaluation of inhaled LTI-03 in a Phase 2 study of longer duration in patients with IPF.

References

1. Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. *N Engl J Med* 2018;378:1811-1823.

2. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers* 2017;3:17074.

3. Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis. *Front Pharmacol* 2022;12

4. Belhassen M, Dalon F, Nolin M, Van Ganse E. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. *Respir Res* 2021;22:135.

5. Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, et al. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. *Cells* 2022;11:143.

6. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. *J Exp Med* 2006;203:2895-2906.

7. Kulshrestha R, Singh H, Pandey A, Mehta A, Bhardwaj S, Jaggi AS. Caveolin-1 as a critical component in the pathogenesis of lung fibrosis of different etiology: Evidences and mechanisms. *Exp Mol Pathol* 2019;111:104315.

8. Fan J, Zheng S, Wang M, Yuan X. The critical roles of caveolin-1 in lung diseases. *Front Pharmacol* 2024;15

9. Sanders YY, Liu H, Scruggs AM, Duncan SR, Huang SK, Thannickal VJ. Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts. *Am J Respir Cell Mol Biol* 2017;56:50-61.

10. Nagaraja MR, Tiwari N, Shetty SK, Marudamuthu AS, Fan L, Ostrom RS, et al. p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling. *Am J Pathol* 2018;188:2207-2222.

11. Tian Y, Li H, Gao Y, Liu C, Qiu T, Wu H, et al. Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis. *Clin Proteom* 2019;16

12. Hohmann MS, Habiel DM, Coelho AL, Verri WA, Hogaboam CM. Quercetin enhances ligand-induced apoptosis in senescent idiopathic pulmonary fibrosis fibroblasts and reduces lung fibrosis in vivo. *Am J Respir Cell Mol Biol* 2019;60:28-40.

13. Fan L, Shetty RS, Dao HM, Balnadupete A, Somasundram B, Bhagavath AK, et al. p53-miR-34a Feedback in Lung Fibroblasts Regulates Antifibrotic Effects of CSP7, Nintedanib and Pirfenidone. *Am J Physiol Lung Cell Mol Physiol* [online ahead of print] 18 Aug 2025; DOI:10.1152/ajplung.00295.2024.

14. Komatsu S, Fan L, Idell S, Shetty S, Ikebe M. Caveolin-1-Derived Peptide Reduces ER Stress and Enhances Gelatinolytic Activity in IPF Fibroblasts. *Int J Mol Sci* 2022;23:3316.

15. Venkatesan S, Fan L, Tang H, Konduru NV, Shetty S. Caveolin-1 scaffolding domain peptide abrogates autophagy dysregulation in pulmonary fibrosis. *Sci Rep* 2022;12:11086.

16. MacKenzie B, Maier E, Creyns B, Coelho AL, Windsor B, M. HC. Caveolin Scaffolding Domain LTI-03 Modulates Both Inflammatory and Fibrotic Responses in Aged Mice After Bleomycin Challenge [abstract]. *Am J Respir Crit Care Med* 2022;205:A2307.

17. MacKenzie B, Mahavadi P, Pinho Jannini-Sa YA, Creyns B, Coelho AL, Espindola M, et al. LTI-03 peptide demonstrates anti-fibrotic activity in *ex vivo* lung slices from patients with IPF. *iScience* 2025;28

18. Jannini-Sa YAP, Coelho AL, Mackenzie B, Hogaboam CM. Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres From IPF and Normal Donor Lung Samples [abstract]. *Am J Respir Crit Care Med* 2025;211:A4691.

19. Marudamuthu AS, Bhandary YP, Fan L, Radhakrishnan V, MacKenzie B, Maier E, et al. Caveolin-1-derived peptide limits development of pulmonary fibrosis. *Sci Transl Med* 2019;11:522:eaat2848.

20. Zhang Y, MacKenzie B, Koleng JJ, Maier E, Warnken ZN, Williams RO, 3rd. Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis. *Mol Pharm* 2020;17:632-644.

21. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018;198:e44-e68.

22. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax* 2003;58:339-343.

23. Tourkina E, Hoffman S. Caveolin-1 signaling in lung fibrosis. *Open Rheumatol J* 2012;6:116-122.

24. Gvaramia D, Blaauboer ME, Hanemaaijer R, Everts V. Role of caveolin-1 in fibrotic diseases. *Matrix Biol* 2013;32:307-315.

25. Shivani G, Lokesh Kumar B. Caveolin-1: A Promising Therapeutic Target for Diverse Diseases. *Curr Mol Pharmacol* 2022;15:701-715.

26. Shetty S, Idell S. Caveolin-1-Related Intervention for Fibrotic Lung Diseases. *Cells* 2023;12:554.

27. Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML, et al. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. *Chest* 2018;154:1359-1370.

28. Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. *Respir Res* 2018;19:32.

29. Permatasari TW, Karuniawati A. Post-Bronchoscopy Infections: A Literature Review. *Journal of Clinical Microbiology and Infectious Diseases* 2024;4:41-49.

30. Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. *Nat Rev Immunol* 2023;23:24-37.

31. Lee JU, Chang HS, Lee HJ, Jung CA, Bae DJ, Song HJ, et al. Upregulation of interleukin-33 and thymic stromal lymphopoietin levels in the lungs of idiopathic pulmonary fibrosis. *BMC Pulm Med* 2017;17:39.

32. Datta A, Alexander R, Sulikowski MG, Nicholson AG, Maher TM, Scotton CJ, et al. Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. *J Immunol* 2013;191:4867-4879.

33. Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, et al. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. *Chest* 2020;158:1526-1534.

34. He X, Ji J, Zheng D, Luo Z, Luo L, Guo L. Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis. *Front Immunol* 2025;16:1450798.

35. Ikeda K, Chiba H, Nishikiori H, Azuma A, Kondoh Y, Ogura T, et al. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. *Respir Res* 2020;21:316.

36. Jenkins RG, Cottin V, Nishioka Y, Noth I, White ES, Ittrich C, et al. Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis. *ERJ Open Research* 2024:00558-02023.

37. Maher TM, Jenkins RG, Cottin V, Nishioka Y, Noth I, Selman M, et al. Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. *ERJ Open Res* 2024;10:00335-02023.

Table 1. Baseline Demographics and Disease Characteristics

Parameter	LTI-03 5 mg/day (N = 9)	LTI-03 10 mg/day (N = 9)	LTI-03 Pooled (N = 18)	Placebo Pooled (N = 6)
Age, yr, mean (SD)	67.8 (9.76)	68.4 (10.79)	68.1 (9.99)	71.7 (6.15)
Male, *n* (%)	7 (77.8)	7 (77.8)	14 (77.8)	6 (100)
Female, *n* (%)	2 (22.2)	2 (22.2)	4 (22.2)	0
Race and Ethnicity, *n* (%)				
White, Not Hispanic or Latino	9 (100)	9 (100)	18 (100)	6 (100)
BMI (kg/m^2), mean (SD)	28.9 (2.73)	29.4 (6.63)	29.1 (4.93)	29.3 (4.99)
Past/current cigarette use, n (%)	8 (88.9)	7 (77.8)	15 (83.3)	4 (66.7)
FVC percent predicted, mean (SD)	84.8 (10.22)	92.1 (18.66)	88.5 (15.08)	75.6 (8.94)
DLCO percent predicted, mean (SD)	59.0 (7.66)*	60.9 (11.70)	60.0 (9.75) [†]	61.4 (10.11)
LCQ total score, mean (SD)	18.2 (3.26)	16.6 (3.24)	17.4 (3.26)	16.1 (3.37)
Cough VAS score, mean (SD)	29.6 (30.65)	38.1 (21.51)	33.8 (26.06)	35.3 (27.20)

Definitions of abbreviations: SD = standard deviation, BMI = body mass index; DLCO = diffusion capacity of the lungs for carbon monoxide; FVC = forced vital capacity; LCQ = Leicester Cough Questionnaire; VAS = Visual Analog Scale

[*]Data available for n=8

[†]Data available for n=17

Table 2. Overview of Treatment-Emergent Adverse Events

Event, *n* (%)	LTI-03			Placebo
	5 mg/day (N = 9)	10 mg/day (N = 9)	Pooled (N = 18)	Pooled (N = 6)
Any TEAE	6 (66.7)	7 (77.8)	13 (72.2)	3 (50.0)
TEAEs leading to treatment discontinuation	0	0	0	0
Serious TEAEs	0	1 (11.1)	1 (5.6)	0
TEAEs related to study drug	2 (22.2)	5 (55.6)	7 (38.9)	1 (16.7)
TEAEs Grade 1	5 (55.6)	5 (55.6)	10 (55.6)	3 (50)
Grade 2	1 (11.1)	2 (22.2)	3 (16.7)	0
≥ Grade 3	0	0	0	0
TEAEs in ≥2 participants				
Cough	3 (33.3)	5 (55.6)	8 (44.4)	2 (33.3)
Rhinorrhea	1 (11.1)	1 (11.1)	2 (11.1)	0

Definitions of abbreviation: TEAE = treatment-related adverse event.

Adverse events were graded following the Common Terminology Criteria for Adverse Events, Version 5, include Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (fatal).

Table 3. Exploratory biomarkers change from baseline

PLASMA							
Analyte	**Treatment Group**	**N**	**Change from Baseline (Mean)**	**SEM**	**Difference**	**90% CI**	**p-value**
SP-D	Placebo	5	1433	4761	-	-	-
	LTI-03 C1	8	7409	6222	5977	-9829, 21782	0.2556
	LTI-03 C2	8	-12739	7656	-14172	-33040, 4697	0.1022
	LTI-03 C1+C2	16	-2665	5429	-4098	-13537, 21732	0.3462

PERIPHERAL BLOOD MONONUCLEAR CELLS							
Analyte	**Treatment Group**	**N**	**Change from Baseline (Mean)**	**SEM**	**Difference**	**90% CI**	**p-value**
%p-AKT	Placebo	6	-1.028	16.19	-	-	-
	LTI-03 C1	9	2.427	11.32	3.455	-30.39, 37.30	0.4297
	LTI-03 C2	9	-4.556	2.896	-3.528	-27.36, 20.30	0.3986
	LTI-03 C1+C2	18	-1.064	5.73	-0.03644	-23.14, 23.06	0.4989

DEEP BRONCHIAL BRUSHINGS							
Analyte	**Treatment Group**	**N**	**Change from Baseline (Mean)**	**SEM**	**Difference**	**90% CI**	**p-value**
COL1A1	Placebo	6	5.959	15.61	-	-	-
	LTI-03 C1	8	0.6593	0.7102	-5.299	-34.40, 23.80	0.3492
	LTI-03 C2	9	-30.71	16.21	-36.66	-78.58, 5.26	0.0727
	LTI-03 C1+C2	17	-15.95	9.217	-21.9	-53.00, 9.194	0.1195
CXCL7	Placebo	6	948.1	979.5	-	-	-
	LTI-03 C1	8	-99.33	103.2	-1047	-2554, 458.7	0.1194
	LTI-03 C2	9	-896.8	520.8	-1845	-3644, -45.50	0.0463
	LTI-03 C1+C2	17	-521.5	289.7	-1470	-2751, -188.7	0.0308
GAL-7	Placebo	6	3337	2495	-	-	-
	LTI-03 C1	8	78.59	901	-3258	-7491, 975.7	0.0977
	LTI-03 C2	9	-640.3	820.6	-3977.3	-7947, -7.083	0.0497
	LTI-03 C1+C2	17	-302	594.5	-3639	-6637, -639.9	0.0246
IL-11	Placebo	6	10.24	17.11	-	-	-
	LTI-03 C1	8	-15.05	9.81	-25.28	-58.37, 7.797	0.0991
	LTI-03 C2	9	-12.43	6.532	-22.67	-50.86, 5.518	0.089
	LTI-03 C1+C2	17	-521.5	289.7	-1470	-47.34, -0.4646	0.0308
TSLP	Placebo	6	11.63	5.678	-	-	-
	LTI-03 C1	7	-6.154	5.289	-17.784	-31.72, -3.836	0.0214
	LTI-03 C2	9	-6.727	4.636	-18.35	-31.33, -5.370	0.0132
	LTI-03 C1+C2	16	-6.477	3.369	-18.1	-29.32, -6.885	0.0057

C1: (Cohort 1; 5 mg/day); C2: (Cohort 2; 10 mg/day); C1+C2; combined LTI-03 cohorts 1 and 2; Placebo participants are pooled for analyses. N: total number of samples; sample sizes are varied due to missing samples or results below the limit of quantification. SEM: standard error of the mean. CI: confidence interval. A one-tailed, unpaired, parametric t-test was performed on the

changes from baseline (pre-dose) to Day 14 in analyte values for placebo vs. C1, C2 or C1+C2. A p-value of ≤ 0.1 was considered statistically significant.

Figure 1: Phase 1b clinical study protocol design. Images reflect spirometry, bronchoscopy, and blood biomarker collection timepoints. Blood for biomarker analyses were collected during screening prior to the bronchoscopy.

Figure 2: Phase 1b clinical study participant disposition

Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study

Philip L. Molyneaux M.D., Nikhil A. Hirani M.D., Collin C.K. Chia M.D., Tejaswini
Kulkarni M.D., Tanzira Zaman, M.D., Robert J. Kaner M.D., Cory M. Hogaboam Ph.D.,
BreAnne MacKenzie Ph.D., Ana Lucia Coelho Ph.D., Yago Amigo Pinho Jannini-Sa Ph.D.,
Brian Windsor Ph.D., Sydney Kruger, Dale J Christensen Ph.D., Steven A. Shoemaker M.D.,
Andreas Günther M.D., Ph.D.

Online Data Supplement

INCLUSION AND EXCLUSION CRITERIA

The complete list of inclusion criteria was as follows:

1. Male or female subject of age 40 years or older.
2. Willing and able to provide written informed consent.
3. Diagnosis of IPF within 3 years of Screening as confirmed by HRCT of chest or lung biopsy as defined by ATS/ERS/JRS/ALAT guideline (E1).
4. Forced vital capacity (FVC) percent predicted $\geq$ 40%.
5. Diffusion capacity of the lungs for carbon monoxide (DLCO) percent predicted $\geq$ 30 and $\leq$ 80.
6. Forced expiratory volume 1 (FEV_1)/FVC $\geq$ 0.7.

The complete list of exclusion criteria was as follows:

1. Interstitial lung disease other than IPF.
2. Evidence of significant obstructive lung disease.
3. Current diagnosis of asthma.
4. Treatment with an approved or investigational anti-fibrotic therapy for IPF within 2 months of the Baseline bronchoscopy.
5. Use of N-acetyl cysteine or other supplements within 7 days prior to dosing and throughout the Treatment Period.
6. Inability to use study inhaler device appropriately.
7. Pulmonary exacerbation within 6 months prior to Screening.
8. Febrile illness within 7 days prior to dosing.
9. Participation in a clinical study or treatment with an investigational drug or device within 30 days of the Screening Visit (or 5 half-lives of the investigational agent, whichever is longer).
10. History or evidence at screening of significant renal impairment with eGFR < 30mL/min.
11. History or evidence at screening of significant hepatic impairment with bilirubin > 3 mg/dL (> 51.3 μmol/L) and albumin < 2.8 g/dL (<28 g/L) and PT prolongation > 6 sec or INR > 2.3.
12. Serious or active medical or psychiatric condition which, in the opinion of the Investigator, may interfere with treatment, assessment, or compliance with the protocol.
13. Vaccination within 2 weeks of start of dosing (Day 1) and throughout the Treatment Period.
14. Subject has severe progressive or uncontrolled, clinically significant disease that in the judgment of the investigator or designee renders the subject unsuitable for the study.
15. Positive pregnancy test in female subjects of childbearing potential as defined below.
16. Female subjects who are lactating.
17. Females of childbearing potential and men with partners of childbearing potential who do not agree to use an acceptable form of contraception for the duration of study treatment and for at least 90 days after the last dose of study drug. Male subjects who do not agree to refrain from donating sperm during this same period.

STUDY ASSESSMENTS

Spirometry

Spirometry was performed during Screening, Day 1, Day 7, Day 14, and Day 21 according to American Thoracic Society (ATS) / European Respiratory Society (ERS) Task Force guidelines (E2). On study drug dosing Days 1, 7, and 14, spirometry was performed pre-dose and then post-dose at 30 and 60 minutes. If bronchospasm was suspected, spirometry may also have been performed before and after a rescue beta-adrenergic agonist inhalation.

Bronchoscopy Sample Collection

Samples collected by bronchoscopy were used to assess LTI-03 lung concentrations and to evaluate pharmacodynamic biomarkers of inhaled LTI-03.

Bronchoscopy was performed to collect deep bronchial brushings (DBB), bronchoalveolar lavage (BAL) fluid, and/or bronchoabsorption (BA) samples at baseline and then on Day 14, approximately 2-3 hours after the participant self-administered their morning dose of study drug (LTI-03 or placebo) and after all other study assessments had been completed.

Deep bronchial brushings were required for all participants; the site had the option to collect either BAL or BA samples, or both, depending on local expertise, training, and procedural confidence. The sequence of procedures was to be BA, BAL, and then brushings to minimize the risk of blood contamination of samples. Sedation, local anesthesia, and post-procedure monitoring were performed according to the investigative site's standard of care. Either oral or nasal bronchoscopy routes were acceptable.

Given significant variations in volume of BAL fluid retrieved and that only two sites successfully collected bronchoabsorption samples, biomarker data presented describe results from DBB samples only.

Deep Bronchial Brushings

Bronchoscopists were instructed to obtain a total of 6 brushings from 3 of the basilar bronchial segments of the right lower lobe: the anterior basilar segment, the lateral basilar segment, and the posterior basilar segment. With the bronchoscope proximal to or within the orifice of the appropriate basilar segment, the brush sheath was to be passed out 5 cm beyond the subsegment orifice, and then the brush fully extended an additional 1 cm for a total of 6 cm beyond the orifice of the subsegmental bronchus. At the desired depth, the sheath was to be gently pulled back and forward for 15 strokes to brush the small airways. The brushing process was repeated using any combination of the 3 basilar segments described above, at the discretion of the bronchoscopist, for a total of 6 six separate brush samples.

Bronchoalveolar lavage

Bronchoscopists were instructed to lavage a total of 150 mL of normal saline, in 30-50 aliquots, to either of the two bronchial segments of the right middle lobe: the lateral segment and the medial segment. If the airways were too small to access the medial or lateral segments, then the bronchoscope could be wedged in the right middle lobe bronchus. With the bronchoscope wedged in the appropriate right middle lobe segment (or right middle lobe bronchus if necessary), 30-50 mL of room temperature or warmed normal saline was injected using an

appropriately sized syringe (e.g., 50-60 ml syringe) via tubing attached to the working channel of the bronchoscope lumen. Using the same syringe, the saline was aspirated out through the lumen. Wall suction into a sterile trap could be used as an alternative to syringe aspiration.

Samples for measurement of LTI-03 lung concentrations were collected from the first aspirate.

Pharmacokinetic Analysis

Blood samples for the measurement of systemic LTI-03 concentrations were collected pre-dose (trough) and +5 minutes after dosing on study Days 1, 7, and 14.

Biomarker Analysis

Blood samples for biomarker assessments in peripheral blood mononuclear cells and platelet rich plasma were collected pre-dose on dosing days.

Following optimization for detection of analytes in IPF matrices, meso-scale discovery electrochemiluminescence (MSD-ECL) assays were performed at BioAgylitix for SP-D (#K1519XR-2, MSD) in plasma and AKT/pAKT (#K15100D-1, MSD) in PBMCs according to manufacturer's instructions.

Protein isolation and preparation of DBB samples for ELISAs were performed as previously described (E3) according to manufacturer's instructions for COL1A1 (#ab210966, abcam), CXCL7 (#LS-F4967-1, LS Bio), GAL7 (#DY1339, R&D Systems), IL-11 (#DY218, R&D Systems), TSLP (#DY1398, R&D Systems).

Statistical Analyses

The primary endpoint of the study was safety. No formal statistical hypotheses were tested. All descriptive statistical analyses were performed using SAS statistical software (Version 9.4). Missing data were not imputed unless otherwise stated. Continuous data were summarized using the mean, SD, median, minimum value, and maximum value. Categorical data were summarized using frequency counts and percentages.

For the biomarker analysis, a 1-tailed, unpaired, parametric t-test was performed was conducted to test the hypothesis that 14-day administration of LTI-03 could upregulate or downregulate exploratory biomarkers of interest. Sample results from the pooled placebo group were compared to the LTI-03 5 mg/day group, LTI-03 10 mg/day group, or the total (combined) LTI-03 groups. Statistical analyses were conducted on the change from baseline (Day 14 minus screening) in analyte levels. Sample sizes varied due to missing samples or the exclusion of individual subject data points when an analyte measurement was below the limit of quantification.

Results included in Table 3 of the manuscript are illustrated as violin plots in **Figure E1**.

REFERENCES

E1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018;198:e44-e68

E2. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338

E3. Espindola MS, Habiel DM, Coelho AL, Parimon T, Chen P, Mikels-Vigdal A, et al. Translational Studies Reveal the Divergent Effects of Simtuzumab Targeting LOXL2 in Idiopathic Pulmonary Fibrosis. Fibrosis (Hong Kong) 2023;1

Figure E1   Exploratory biomarkers, change from baseline compared to placebo. A one-tailed, unpaired, parametric t-test was performed on the changes from baseline (pre-dose) to Day 14 in analyte values for placebo vs. LTI-03 5 mg/day, LTI-03 10 mg/day or pooled LTI-03. Differences from placebo are represented as point estimates with 90% confidence intervals. A p

value of ≤ 0.1 was considered statistically significant. N: total number of samples; sample sizes are varied due to missing samples or results below the limit of quantification. DBB = deep bronchial brushings; SP-D = surfactant protein D; %P-AKT = percent phospho-AKT = COL1A1 = collagen type 1 alpha chain1; CXCL7 = chemokine (C-X-C motif) ligand 7; GAL-7 = galectin 7; IL-11 = interleukin 11; TSLP = thymic stromal lymphopoietin.